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Abstract
Heavy chain diseases (HCD) are B-cell lymphoprolipherative disorders characterized by the production of monoclonal heavy chains without asso-
ciated light chains. Some cases of gamma-HCD (γ-HCD) are concurrent with other lymphoid neoplasm. The monoclonal component is not always 
detectable by serum electrophoresis, and often an immunofixation procedure is necessary to detect this component. Prognosis is variable, and no 
established guidelines for follow-up are available. We describe a case of a challenging diagnosis of γ-HCD due to the absence of clinical signs frequ-
ently reported in the disease (anaemia and palatal oedema among others). Haematological malignancy was the first suspicion but bone marrow 
examination was negative. In addition, the presence of an autoimmune bicytopenia and a Klinefelter syndrome complicated the clinical context of 
the patient. A thoracoabdominal computed tomography reported many small adenopathies whose pathological and immunohystochemical study 
revealed a follicular lymphoma. Shortly after, serum inmunofixation secondary to an abnormal electrophoretic pattern revealed a gamma para-
protein without light chains. Eventually, γ-HCD in association with follicular lymphoma was the final diagnosis. This is the first case reporting this 
association.
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Heavy chain disease (HCD) is a rare B-cell lym-
phoproliferative disorder characterized by the 
production of monoclonal, abnormally truncated, 
immunoglobulin heavy-chain proteins (alpha, 
gamma, and/or mu) without associated light 
chains (1,2). Heavy chain disease can be thought of 
as a variant of non-Hodgkin’s lymphoma. Clinical 
manifestations depend on the chain isotype in-
volved and range from asymptomatic to aggres-
sive lymphoma. Prognosis is variable, and no 
standardized effective treatment programs are 
available (2,3).
Gamma-HCD (γ-HCD), also known as Franklin’s dis-
ease, was reported for the first time in 1964. Since 
then, approximately 130 cases have been de-
scribed in the literature (4). Although γ-HCD has 
been reported to occur equally in men and wom-
en, a slight predominance in women has recently 
been noted (5). The median age of diagnosis is 65 
years old (3).
Classic presentation includes generalized lymphad-
enopathies and splenomegaly (2). The most distinc-
tive symptom is palatal oedema resulting from en-
largement of nodes in Waldeyer’s ring, sometimes 
leading to respiratory compromise (3,5).
Gamma-HCD has no specific histopathologic pat-
tern. The most frequent histopathological finding 
is a pleomorphic malignant lymphoplasmacytic 
proliferation in bone-marrow and lymph nodes. 
Aspirate and biopsy specimens may show an in-
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crease in plasma cells, lymphocytes, and/or plas-
macytoid lymphocytes (similar to the bone-mar-
row findings in Waldenström macroglobulinemia) 
(3,6). Nevertheless, in some cases γ-HCD are con-
current with other lymphoid neoplasms, including 
Hodgkin and non-Hodgkin lymphomas, which 
usually precede the serologic diagnosis of γ-HCD 
(2,7,8).
One third of these cases are associated with auto-
immune diseases such as rheumatoid arthritis, au-
toimmune haemolytic anaemia, or idiopathic 
thrombocytopenic purpura (5,6). Some authors di-
vide γ-HCD into three broad categories based on 
the underlying pathologic process and its distribu-
tion: 1) those with disseminated proliferative dis-
ease (55 - 60%); 2) those with localized prolifera-
tive disease (25%); and 3) those with no apparent 
proliferative disease (10 - 15%) (3,6).
In this study, we present a case of a 50-year male 
with gamma heavy chain disease accompanied 
with follicular lymphoma, a subtype of non-Hodg-
kin lymphoma according to WHO classification (9), 
and explain the challenge of its diagnosis.
Case report
A 50-year-old obese, male smoker with excessive 
alcohol consumption and a medical history of 
chronic obstructive pulmonary disease was re-
ferred for a haematology consultation due to a bi-
cytopenia detected during a routine examination 
in October 2016. No masses or visceromegaly were 
found during first physical exam. Following physi-
cal exam, haematology and biochemical analyses 
were performed. Samples for complete blood 
count (CBC) were collected from the cubital veins 
into blood collection Vacuette® tubes with K3EDTA 
(Greiner Bio-one, Kremsmunster, Austria) and were 
measured on Sysmex XN 9000 (Sysmex, Kobe, Ja-
pan) whereas peripheral blood smear was per-
formed by microscopy. Samples for biochemical 
analysis were collected into blood collection Vacu-
ette® tubes with serum clot activator and gel 
(Greiner Bio-one, Kremsmunster, Austria) for as-
partate-aminotranspherase (AST), lactate dehy-
drogenase (LD), beta(β)-2 microglobulin and C-re-
active protein (CRP), and were measured on the 
Cobas 8000 (Roche Diagnostics, Mannheim, Ger-
many). Laboratory findings on admission are sum-
marized in Table 1. Considering CBC, the results 
obtained indicated neutropenia and thrombocy-
topenia whereas haemoglobin was normal. A pe-
ripheral blood smear did not show dysplastic fea-
tures for any haematopoietic lineage and had no 
circulating blasts or erythroblasts. Biochemical in-
dicators of liver function were slightly increased, 
while the β-2 microglobulin concentration was 
above the normal values.
In suspicion of haematological malignancy, a bone 
marrow aspirate and biopsy were requested. They 
showed normocellular bone marrow with the 
presence of three haematopoietic lineages with 
no remarkable dysplastic features and no matura-
tion arrest in granulocytic lineage. There was no 
evidence of infiltration of either tumour cells or 
atypical lymph cells. An incidental finding such as 
a chromosomal abnormality (47, XXY) was detect-
ed by cytogenetic study. He was diagnosed with 
Klinefelter syndrome. 
Since the bone marrow study was negative, immu-
nological examination including antinuclear anti-
bodies, anti-mitochondrial, anti-gastric parietal 
cells, and anti-smooth-muscle was performed by 
indirect immunofluorescent tests using the com-
mercially available kit NOVA Lite Rat (Inova Diag-
nostics, San Diego, California). All tests were nega-
tive. Furthermore, immunoglobulin (Ig) A, G, and 
M serum concentrations were investigated on Im-
mage 800 analyser (Beckman Coulter, Brea, Cali-
fornia). Results are presented in Table 1. 
Additionally, different serological tests were exam-
ined: hepatitis and HIV on Cobas e411 (Roche diag-
nostics, Mannheim, Germany); mumps, Epstein-
Barr virus and cytomegalovirus on Liaison (Diasor-
in, Saluggia, Italy). All these tests were negative 
(Table 1). 
Following serological examination, serum electro-
phoretic pattern was evaluated on Capillarys 2 (Se-
bia, Lisse, France). At that moment it was normal as 
shown in Figure 1A. Finally, presence of antibodies 
by immunofluorescence was investigated and re-
sults revealed presence of IgG and IgM anti-neu-
trophil antibodies, attached to cell surface (direct 
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Test group Parameter Admission (October 2016)
Follow up 
(February 2017) Reference intervals
CBC
WBC (x109/L) 1.3 1.33 4-11
Neutrophils (x109/L) 0.1 0.48 2.5-7.5
Lymphocytes (x109/L) 0.52 0.31 1-4.5
Monocytes (x109/L) 0.59 0.43 0.2–1.0
Haemoglobin (g/L) 143 166 130-175
Platelets (x109/L) 54 93 130-400
Chemistry
AST (U/L) 47 44 0-38
LD (U/L) 308 251 135-225
β-2 MG (µg/mL) 3.7 3.9 0.8-2.2
CRP (mg/L) 44 - 0-5
Immunology
IgG (g/L) 7.64 10.60 7.00–16.00
IgA (g/L) 0.90 1.37 0.7–4.0
IgM (g/L) 3.62 4.03 0.4-2.3
Serology
HBSAG Negative - Negative
HBCAC Negative - Negative
HCAC Negative - Negative
HIVAC Negative - Negative
EBIGM Negative - Negative
EBIGG Positive - Negative
CMVIGM Negative - Negative
CMVIGG Positive - Negative
MUMPSIGG Negative - Negative
MUMPSIGM Negative - Negative
Autoimmunity
Anti-neutrophil antibodies Positive* - Negative
Anti-platelet antibodies Positive† - Negative
*Presence of IgG and IgM anti-neutrophil antibodies attached to cell surface (direct test) and free in serum (indirect test).
†IgG anti-platelet antibodies (cut-off > 30%). CBC - complete blood count. WBC - white blood cell count. AST – aspartate-amino-
transferase. LD – lactate-dehydrogenase. B-2 MG - beta-2 microglobulin. CRP - C - reactive protein. Ig – immunoglobulin. CMV – 
cytomegalovirus. HIV - human immunodeficiency virus. EB - Epstein-Barr virus. HBSAG - hepatitis B surface antigen index (cut-off 
< 1). HBCAC - anti-hepatitis B core antigen index (cut-off > 1). HCAC - hepatitis C antibody index (cut-off < 1). HIVAC - human 
immunodeficiency virus antibody + p24 antigen index (cut-off < 1). EBIGM - IgM antibodies to Epstein-Barr viral capsid antigens 
(cut-off < 20 U/mL). EBIGG - IgG antibodies to Epstein-Barr viral capsid antigens (cut-off < 20 U/mL). CMVIGM - IgM antibodies to 
human cytomegalovirus (cut-off < 18 U/mL). CMVIGG - IgG antibodies to human cytomegalovirus (cut-off < 12 U/mL). MUMPSIGM 
- IgM antibodies to mumps index (cut-off < 0.9). MUMPSIGG - IgG antibodies to mumps index (cut-off < 0.9)
Table 1. Laboratory findings on admission and during follow up
test) and free in serum (indirect test). In addition, 
anti-platelet antibodies analysed by flow cytome-
try (IgG and IgM antibodies detection by direct 
test) were positive (Table 1). These data introduced 
the possibility that the origin of bicytopenia was 
autoimmune.
Thoracoabdominal computed tomography (CT) 
performed in November 2016 showed modest sple-
nomegaly and many small supra- and infra- dia-
phragmatic adenopathies, even though they were 
not palpable. Radiology-guided biopsy was then 
performed in an inguinal adenopathy. According to 
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the pathologist, the histological sections showed a 
lymph node with an unstructured architecture due 
to the proliferation of medium to large-sized lym-
phocytes with vesicular chromatin and nucleoli 
(centroblasts) and some other smaller cells (centro-
cytes). The biopsy was submitted to immunohysto-
chemical study showing cells that were positive to 
CD20, CD79a, BCL-6, CD10, LMO2 and BCL-2 (SP-66). 
It was also observed a diffuse area completely lack-
ing follicles defined by CD21+/CD23+. It was finally 
defined as a follicular lymphoma grade 3 (a type of 
lymphoproliferative syndrome type B) based on the 
2008 WHO classification. 
Four months later, in February 2017, laboratory 
analyses were repeated. Neutropenia and throm-
bocytopenia were similar (Table 1). Haemoglobin 
was still normal. Serum electrophoresis was per-
formed again, and an abnormal electrophoretic 
pattern suggestive of a monoclonal component in 
the gamma region was seen (Figure 1B). Serum im-
munofixation was performed on Hydrasys (Sebia, 
Lisse, France) and revealed a gamma paraprotein 
with no associated monoclonal light chains (kappa 
or lambda) which explains the spike observed in 
gamma region of the electrophoresis. The serum 
concentration of gamma protein quantified by 
densitometry was 5.15 g/L (Figure 2). Electropho-
resis was also performed in a 24 hour urine sample 
that contained 0.1 g of protein measured by Cobas 
8000 (Roche Diagnostics, Mannheim, Germany) 
and it did not show a monoclonal spike.
Eventually, the patient was diagnosed with γ-HCD 
associated with lymphoproliferative syndrome 
type B (follicular lymphoma).
Figure 1. Serum electrophoresis of 50-year old male patient with heavy chain disease accompanied with follicular lymphoma on ad-
mission and after four months. A - Patient´s first serum electrophoresis showing normal pattern. B - Patient´s second serum electro-
phoresis after four months, with monoclonal spike in gamma globulin fraction. a-1 - alpha-1 globulin fraction. a-2 - alpha-2 globulin 
fraction. b - beta globulin fraction. g - gamma globulin fraction.
Albumin α-1 α-2 β γ Albumin α-1 α-2 β γ
A B
Figure 2. Agarose serum electrophoresis with immunofixation 
of the patient with gamma heavy chain disease accompanied 
with follicular lymphoma. Monospecific antisera were applied 
to five of the electrophoresis lanes as follows: G - anti-gamma 
heavy chain; A - anti-alpha heavy chain; M - anti-mu heavy 
chain; K - anti-kappa light chain; L - anti-lambda light chain. 
Results showing monoclonal band gamma in gamma fraction 
(denoted by band seen in G line) without any associated light 
chain monoclonal band (faint polyclonal pattern are seen in L 
and K lanes).
ELP - electrophoretic pattern from patient. ALB - albumin re-
gion. α-1 - alpha-1 globulin region. α-2 - alpha-2 globulin re-
gion. β - beta globulin region. γ - gamma globulin region.
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In March 2017, the patient started corticosteroid 
treatment (prednisone) but it stopped 10 days lat-
er due to an ascitic decompensation, probably due 
to an alcoholic hepatitis. At present, no haemato-
logical treatment has begun but the patient is fol-
lowing a close monitoring by haematologist. Once 
the liver problem is stabilized, the patient will be 
candidate for R-CHOP therapy (Rituximab with cy-
clophosphamide, adryamicine, vincristine and 
prednisone) to treat his follicular lymphoma. 
Discussion
In the present study, we describe a case of 50-year 
male with g-HCD accompanied with follicular lym-
phoma.
Classic presentation of g-HCD includes generalized 
lymphadenopathies and splenomegaly also 
shown by our patient by CT, but not at physical ex-
amination (2). One of the most distinctive symp-
toms is palatal oedema resulting from enlarge-
ment of nodes in Waldeyer’s ring (4,5). Our patient 
did not present this symptom. Although our pa-
tient did not present with anaemia, it is frequent 
and usually normocytic, normochromic, and mod-
erate in g-HCD (3,5).
Gamma-heavy chain disease has no specific histo-
pathological pattern. The most frequent histo-
pathological finding is a pleomorphic malignant 
lymphoplasmacytic proliferation in bone marrow 
and lymph nodes (3,6). These features of HCD infil-
tration were not found in our patient. Bone mar-
row was normal and lymph node presented a pat-
tern of infiltration that was defined as a follicular 
lymphoma. 
Approximately one third of described γ-HCD de-
velop as a composite lymphoid neoplasm (2,7,10). 
In 2013, Beliauskas et al. made a description of 13 
cases of HCD, five of which were associated to lym-
phoproliferative disorders (splenic diffuse red pulp 
small B-cell lymphoma, splenic marginal-zone 
lymphoma, mucosa-associated lymphoid tissue 
(MALT) lymphoma, lymphoplasmacytic lympho-
ma and monoclonal gammopathy of undeter-
mined significance) (2). However, most of the cases 
described by these authors were associated to au-
toimmune disease, such as lupus erythematosus, 
autoimmune thyroiditis and rheumatoid arthritis 
(2). In 2016, Iijima et al. describe a case of γ-HCD 
with T-cell large granular lymphocytic leukaemia 
(7). They conducted a literature review of compos-
ite cases described since 2000. Most of them were 
Hodgkin lymphomas, T-cell large granular lym-
phocyte leukaemia, diffuse large B-cell lymphoma 
and splenic marginal-zone lymphoma, among 
others. As they remarked in their paper, most cas-
es in the literature were classified by old criteria 
and lacked sufficient information about cytoge-
netics and histopathological pattern. It is impor-
tant to emphasise that no case of follicular lym-
phoma has been described in association with 
γ-HCD in the current literature. Our case is the first 
reporting this association.
The patient had an autoimmune bicytopenia. Auto-
immune disorders are found in about one third of 
γ-HCD cases, most frequently rheumatoid arthritis, 
but also autoimmune haemolytic anaemia, idio-
pathic thrombocytopenic purpura, vasculitis, 
Sjögren syndrome or thyroiditis (5,6,8). Since bone 
marrow examination did not show lymphoma in-
volvement, we excluded that patient’s bicytopenia 
could be secondary to lymphoproliferative infiltra-
tion. Nevertheless, antibodies against neutrophils 
and platelets were detected suggesting the pres-
ence of an autoimmune neutropenia and thrombo-
cytopenia. Autoimmune haemolytic anaemia and 
immune thrombocytopenia has been described 
previously in the literature associated with γ-HCD 
whereas immune neutropenia is not a common 
finding in this setting (5,8). The rest of the immuno-
logical examination, including antinuclear, anti-mi-
tochondrial, anti-gastric parietal cells, and anti-
smooth-muscle antibodies, was negative. 
During the cytogenetic study, a chromosomal ab-
normality (47, XXY) was detected. It is common to 
diagnose Klinefelter syndrome in the adulthood as 
a consequence of infertility studies. Patients with a 
47, XXY karyotype appear to have an increased risk 
of developing a malignancy in adulthood, usually 
breast cancer, extragonadal germ cell tumour and 
acute myeloid leukaemia. Several studies associate 
Klinefelter syndrome and haematological disease 
(11,12). Patients with excess chromosomes in cells 
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(Down syndrome, etc.) may have high frequency 
of chromosome translocation or gene fusion dur-
ing cell division (leading to the development of a 
haematological malignancy). Nevertheless, no evi-
dence of association of Klinefelter syndrome and 
γ-HCD has been described in the literature. 
Diagnosis of γ-HCD has certain difficulties and it 
represents an added challenge for the laboratory 
analyst. The monoclonal spike that appeared on 
the protein gel was essential for an accurate diag-
nosis of γ-HCD. The diagnosis can easily be missed 
because in 20 - 40% of cases no monoclonal spike 
is observed in the serum electrophoretic profile 
(3). Indeed, the first serum sample from our pa-
tient showed an electrophoretically normal pat-
tern. Four months later, we detected a monoclonal 
spike that was confirmed by serum immunofixa-
tion (Figure 1). Thus, in those cases with a strong 
diagnostic suspicion of gammopathy or lymphoid 
neoplasm, we recommend serialization every 2 - 3 
months of the electrophoretic serum pattern. 
Even if there is a normal electrophoretic profile, in 
these cases, we perform serum immunofixation.
The absence of free light chains can cause amount 
of HCD protein in the urine to be unusually small 
(3). Presently, urine samples of our patient have 
not presented any monoclonal component. 
Upon finding a heavy chain monoclonal band in 
immunofixation, one should be aware that differ-
ing sensitivity of heavy and light chain reagents 
could potentially cause false negative results in 
light chain immunofixation. This would incorrectly 
suggest a diagnosis of HCD in cases of a regular, 
intact monoclonal gammopathy (4).
At this time, no standardized effective treatment 
programs for HCD are available (2,3). Most patients 
with low-grade lymphoplasmacytic infiltrates ap-
pear to respond to non-anthracycline-containing 
chemotherapy, and responses to rituximab have 
been reported (9). Some authors have described 
their treatment experiences. Takano et al. treated 
successfully a γ-HCD patient for the first time with 
rituximab in combination with standard chemo-
therapy (13). Inoue et al. (14) used a single course of 
combination immunochemotherapy, which con-
sisted of rituximab and fludarabine. The patient re-
mained in good clinical condition and transfusion 
independent. Our patient has not yet received any 
treatment until the hepatic problem is solved. Fol-
licular lymphoma has well established treatment 
protocols including chemotherapy combination 
(anthracyclines) and anti-CD20 monoclonal thera-
py with rituximab.
In conclusion, γ-HCD is an extremely rare disease 
with a challenging diagnosis due to both uncer-
tain clinical context and variable symptomatology. 
One third of cases develop as a composite lym-
phoid neoplasm. We have described a case of 50-
year male with γ-HCD associated with follicular 
lymphoma for the first time. The diagnosis can 
easily be missed because serum protein electro-
phoresis does not always suggest a monoclonal 
gammopathy. Serum immunofixation is the only 
definitive procedure for demonstrating the exist-
ence of monoclonal heavy-chain paraproteins. We 
believe that our experience may help other profes-
sionals to handle a similar diagnosis.
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